Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Moreau KL, King JA
Key findings relevant to nausea included: Nausea was most prevalent during the dose-escalation phase and tended to diminish over time as participants adapted to the medication Higher doses were associated with higher rates of nausea and vomiting The majority of gastrointestinal events were transient and self-limiting Discontinuation due to gastrointestinal side effects occurred in a small but notable proportion of participants, particularly in higher-dose groups It should be noted that the weight-loss outcomes described above are from a Phase 2 trial and cannot be directly compared with those of licensed medicines without head-to-head data
Attend all scheduled follow-up appointments, which typically include assessment of weight loss velocity, glycaemic control, and adverse effects
doi: 10.1074/jbc.M304951200
Dyslipidemia, alcohol consumption, and obesity as main factors associated with poor control of urate levels in patients receiving urate-lowering therapy
